GSK PLC (GSK) reports robust sales growth and upgrades its full-year guidance, driven by strong performance in specialty medicines and oncology.

GlaxoSmithKline ( ($GB:GSK) ) has shared an announcement. GSK has announced the purchase of 175,000 of its own ordinary shares as part of its ...

Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40-billion-pound sales projection ...

GSK’s fair value estimate has seen a modest increase, rising from $16.63 to $17.36 per share. The discount rate remains ...

Fintel reports that on November 3, 2025, Jefferies reiterated coverage of GSK plc - Depositary Receipt (NYSE:GSK) with a Buy ...

British Big Pharma GSK is welcoming President Donald Trump to the U.K. with a hefty gift: a five-year, $30 billion planned investment in U.S. R&D and manufacturing. The funds are set to be spread ...

GSK now owns the global development and commercialisation rights to Empirico's COPD-targeting (siRNA) oligonucleotide, ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential functional cure for the infectious disease. On a media call Wednesday morning to ...

GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.